• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Better Therapeutics to cut 35% of workforce

Better Therapeutics to cut 35% of workforce

March 27, 2023 By Sean Whooley

Better Therapeutics BT-001 diabetes digital therapeutic
BT-001 [Image from Better Therapeutics website]
Better Therapeutics (Nasdaq:BTTX) announced that it commenced a workforce reduction of approximately 35% of its employees.

Per the digital therapeutic developer’s most recent annual report, it had 44 employees as of Dec. 31, 2021. The layoffs could affect as many as 15 employees if the headcount remains similar.

In an SEC filing, Better Therapeutics said the headcount cut comes as part of a cost reduction initiative. It aims to improve its cash runway and “focus on the long-term success of the company.” According to the filing, the company planned to complete the reduction on March 24 with about $400,000 in cash-based expenses related to severance and benefits in the second quarter of 2023.

Better Therapeutics is not the only digital therapeutic developer to enforce layoffs recently. Both Pear Therapeutics and Akili slashed their workforces. Here’s a list of recent layoffs around the medtech industry.

Shares of BTTX fell 4.7% to 85¢ apiece in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.4%.

Better Therapeutics CEO pens letter to employees

CEO Frank Karbe sent an email to Better Therapeutics employees on March 23, announcing the workforce reduction. In it, Karbe wrote that the company is implementing cost-saving actions to further extend its financial runway ahead of “critical milestones.”

Those include, over the next few months, potential FDA marketing authorization and a subsequent launch for BT-001. BT-001 is a digital therapeutic for treating type 2 diabetes. The company submitted an FDA de novo request in September 2022 for the therapeutic.

“Layoffs are devastating for everyone,” Karbe wrote in the letter, which was included in the SEC filing. “As CEO, I take responsibility. While this does not ease the pain, I recognize today was an extremely difficult day.”

Karbe went on to say that the company reached a “critical moment” in its evolution ahead of potential regulatory nods. With challenges spanning the industry, Karbe and the company felt they had to enact the layoffs.

“As we navigate volatility and uncertainty in the markets, it has become clear that we need to take action to preserve our cash runway,” he wrote.

Filed Under: Business/Financial News, Diabetes, Digital Health, Featured, Health Technology, News Well, Software / IT Tagged With: Better Therapeutics, Personnel Moves

More recent news

  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal
  • How 5 medtech CEOs design for access
  • Butterfly Network to chase ultrasound brain-computer interfaces with newcomer Bridge Neurotech

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy